FDA Chief Admits He Overhyped Plasma Treatment Against COVID: ‘Criticism Is Entirely Justified’

FDA Commissioner Stephen Hahn looks during a coronavirus press briefing, in the James Brady Press Briefing Room at the White House March 19, 2020 in Washington, DC. (Photo by Brendan Smialowski / AFP) (Photo by BREND... FDA Commissioner Stephen Hahn looks during a coronavirus press briefing, in the James Brady Press Briefing Room at the White House March 19, 2020 in Washington, DC. (Photo by Brendan Smialowski / AFP) (Photo by BRENDAN SMIALOWSKI/AFP via Getty Images) MORE LESS
|
August 25, 2020 8:31 a.m.

Food and Drug Administration Commissioner Stephen Hahn conceded on Monday night that he had exaggerated the effectiveness of convalescent plasma therapy as treatment for COVID-19 the day before.

“I have been criticized for remarks I made Sunday night about the benefits of convalescent plasma. The criticism is entirely justified,” Hahn tweeted. “What I should have said better is that the data show a relative risk reduction not an absolute risk reduction.”

The official clarified that the agency’s emergency approval of the treatment “is not a final approval” and that FDA scientists will “continue to monitor its use and will revoke authorization if needed.”

“We feel broader use of plasma will truly benefit many patients but will require further study,” he tweeted.

Newsletters
Get TPM in your inbox, twice weekly.
Your subscription could not be saved. Please try again.
Your subscription has been successful.

Hahn also denied that the authorization, which had been touted by President Donald Trump in his desperate efforts to bolster his reelection chances, was motivated by politics even as Trump pressures the FDA to approve treatment by November.

“We at FDA do not permit politics to enter into our scientific decisions,” Hahn tweeted. “This happens to be a political season but FDA will remain data driven.”

During a press briefing with Trump on Sunday, Hahn had heaped praise upon convalescent plasma therapy, claiming it had reduced the mortality rate among COVID-19 by as much as 35 percent.

“We dream in drug development of something like a 35 percent mortality reduction,” the FDA official said. “This is a major advance in the treatment of patients. This is a major advance.”

Latest News
Comments are now Members-Only

Non-members are still able to read comments, but will no longer be able to participate. To join the conversation, sign up now and get:

30% Off Annual Prime Membership

TPM strives to build as inclusive a community as financially possible. We offer FREE memberships to those experiencing financial hardship and FREE memberships for students.

View all options
Comments
Masthead Masthead
Founder & Editor-in-Chief:
Executive Editor:
Managing Editor:
Associate Editor:
Editor at Large:
General Counsel:
Publisher:
Head of Product:
Director of Technology:
Associate Publisher:
Front End Developer:
Senior Designer: